1. Key Insights

2. Report Introduction

3. Head and Neck Cancer (HNC) -Market Overview at a Glance
3.1. Market Share (%) Head and Neck Cancer (HNC) by Therapies in 2019
3.2. Market Share (%) of Head and Neck Cancer (HNC) by Therapies in 2032

4. Head and Neck Cancer (HNC) - Future Prospects

5. Executive Summary of Head and Neck Cancer
5.1. Quick Insights

6. Key Events

7. Disease Background and Overview
7.1. Introduction
7.2. Signs and Symptoms
7.3. Risk Factors and Causes
7.4. Pathophysiology
7.4.1. HPV-negative HNSCC
7.4.2. HPV-positive HNSCC
7.4.3. Genomic alterations and key pathways
7.5. Diagnosis
7.6. Diagnostic Guidelines
7.6.1. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis
7.6.2. Diagnosis of Squamous Cell Carcinoma of Unknown Primary (SCCUP) in the head and neck: ASCO Guideline

8. Treatment and Management
8.1. Treatment Algorithms
8.2. Treatment and Management Guidelines
8.2.1. Squamous cell carcinoma of the oral cavity, larynx, oropharynx, and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for treatment
8.2.2. Management of Squamous Cell Carcinoma of Unknown Primary (SCCUP) in the head and neck: ASCO Guideline
8.2.3. HNC: NCCN Treatment Guidelines

9. Methodology

10. Epidemiology and Patient Population
10.1. Key Findings
10.2. Assumptions and Rationale 7MM
10.3. Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM
10.4. The United States
10.4.1. Total Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.1. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.2. Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.3. Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.4.4. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States
10.5. EU-5
10.5.1. Total Incident Cases of Head and Neck Cancer (HNC) in EU-5
10.5.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5
10.5.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5
10.5.4. Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in EU-5
10.5.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5
10.6. Japan
10.6.1. Total Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.2. HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.3. Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.4. Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in Japan
10.6.5. Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan

11. Appendix
11.1. Report Methodology
11.2. Bibliography

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

List of Tables
Table 1: Summary of Head and Neck Cancer (HNC) (2019-2032)
Table 2: Key Events
Table 3: Work-up for Staging and Diagnosis
Table 4: NCCN Treatment Guidelines for HNC
Table 5: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019-2032)
Table 6: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Table 7: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Table 8: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Table 9: Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Table 10: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Table 11: Total Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Table 12: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Table 13: Site-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Table 14: Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Table 15: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Table 16: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Table 17: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Table 18: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Table 19: Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Table 20: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)

List of Figures
Figure 1: HNC Regions
Figure 2: Symptoms of HNC
Figure 3: Progression of HNSCC and key Genetic Events
Figure 4: Development of Carcinogen-associated, HPV-negative HNSCC
Figure 5: HPV Infection of the Tonsil Crypt and Development of HPV-positive HNSCC
Figure 6: Treatment Options in Locally Advanced SCCHN (SEOM Clinical Guidelines)
Figure 7: Algorithm for Treatment Decision-making for Recurrent and/or Metastatic HNSCC
Figure 8: Proposed Treatment Algorithm in the First-line Setting for Patients With Recurrent and/or Metastatic HNSCC
Figure 9: Proposed Treatment Algorithm in the Second-line Setting for Patients With Recurrent and/or Metastatic HNSCC
Figure 10: Proposed Treatment Algorithm for Recurrent and/or Metastatic HNSCC Patients After Exposure to First-line Immunotherapy +/? Chemotherapy
Figure 11: Total Incident Cases of Head and Neck Cancer (HNC) in the 7MM (2019-2032)
Figure 12: Total Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Figure 13: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Figure 14: Site-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Figure 15: Molecular Alteration-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Figure 16: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in the United States (2019-2032)
Figure 17: Total Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Figure 18: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Figure 19: Site-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Figure 20: Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Figure 21: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in EU-5 (2019-2032)
Figure 22: Total Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Figure 23: HPV-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Figure 24: Site-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Figure 25: Molecular Alteration -specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)
Figure 26: Stage-specific Incident Cases of Head and Neck Cancer (HNC) in Japan (2019-2032)